Loncastuximab Tesirine
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 95 publications
Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience.
Journal: European journal of haematology
Published: February 23, 2026
Acquired bone marrow aplasia and long-lasting complete remission with Loncastuximab Tesirine in a patient with transformed marginal zone lymphoma: a case report.
Journal: Annals of hematology
Published: February 05, 2026
Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell Therapy.
Journal: European journal of haematology
Published: January 28, 2026
Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL.
Journal: Blood reviews
Published: November 27, 2025
Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Journal: Systematic reviews
Published: November 09, 2025
Chemical evolution of antibody-drug conjugates focused on linker design and conjugation strategies in hematology.
Journal: Seminars in hematology
Published: September 17, 2025
Therapeutic monoclonal antibodies repurposing in oncology via IMGT/mAb-KG embeddings.
Journal: BMC medical informatics and decision making
Published: August 08, 2025
Deep Learning-Based Body Composition Analysis for Outcome Prediction in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Insights From the LOTIS-2 Trial.
Journal: JCO clinical cancer informatics
Published: July 16, 2025
Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system.
Journal: PloS one
Published: July 02, 2025
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.
Journal: Leukemia & lymphoma
Published: June 30, 2025
Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma.
Journal: Cancers
Published: June 29, 2025
Last Updated: 06/30/2026